|
|
Abstract |
|
|
Vol 47 No. 3: 207-213 |
[PDF] [Full Text] |
|
Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways |
|
Chunfang Ma,
Yin Wang,
Lei Dong,
Minjing Li and
Wanru Cai*
|
|
The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou 310005, China |
|
Abstract Resveratrol, the most important ingredient extracted from Polygonum cuspidatum, exerts cytoprotective effects via anti-inflammatory actions in vitro. In this study, we investigated this effect of resveratrol on the lipopolysaccharide (LPS)-induced inflammatory response and its underlying molecular mechanism of action in RAW264.7 murine macrophages. Results showed that resveratrol down-regulated the expression of inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6), therefore, suppressed the production of nitric oxide and the secretion of IL-6 in LPS-stimulated RAW264.7 cells in a dose-dependent manner. Resveratrol also inhibited the translocation of high-mobility group box 1 (HMGB1) from the nucleus to the cytoplasm and of nuclear transcription factor kappa-B (NF-κB) p65 from the cytoplasm to the nucleus; it suppressed the phosphorylation of IκBα. Furthermore, these actions were mediated by suppressing the phosphorylation of signal transducer and activator of transcription (STAT)-1 and -3. In conclusion, these data indicate that resveratrol exerts anti-inflammatory effects, at least in part by reducing the release of HMGB1 and modulating the NF-κB and Janus kinase/STAT signaling pathways. Resveratrol could potentially be developed as a useful agent for the chemoprevention of inflammatory diseases. |
|
Keywords resveratrol; anti-inflammatory; high-mobility group box 1; NF-κB; JAK/STAT |
|
Received 2014-11-7
Accepted 2014-12-8 |
|
Funding This work was supported by the grants from the National Natural Science Foundation of China (No. 81273678) and the Foundation of Zhejiang Traditional Chinese Medicine Projects (No. 2013ZQ016). |
|
* Correspondence address Tel/Fax: +86-571-88064725; E-mail: [email protected] |
|
Browse:216 |
|
|
|
|
Manuscript Submission |
|
|
|
|